Acceleron Pharma Inc.
Methods of treating a fibrotic disorder by administering transforming growth factor beta receptor II fusion polypeptides

Last updated:

Abstract:

In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T.beta.RII polypeptide useful to selectively antagonize a T.beta.RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF.beta. associated disorders.

Status:
Grant
Type:

Utility

Filling date:

30 Jan 2020

Issue date:

18 May 2021